Back to top
more

Ultragenyx Pharmaceutical (RARE)

(Delayed Data from NSDQ)

$44.86 USD

44.86
604,658

-0.20 (-0.44%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Does Ultragenyx (RARE) Have the Potential to Rally 87.43% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Ultragenyx (RARE) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.

Ultragenyx (RARE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat

by Zacks Equity Research

Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.

Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -6.64% and 2.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Reports Next Week: What You Should Expect

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Doses First Patients in Bone Disease Studies

by Zacks Equity Research

Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.

Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?

by Zacks Equity Research

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?

by Zacks Equity Research

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study

by Zacks Equity Research

Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with osteogenesis imperfecta.

Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing

by Zacks Equity Research

Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.

Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Zymeworks Inc. (ZYME) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Ultragenyx (RARE): Can Its 6.7% Jump Turn into More Strength?

by Zacks Equity Research

Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.